Spending on R&D by midmarket biotech companies increased 18 percent from 2015 to 2016, from an average of $65.9 million to an average of $80.6 million, according to the 2017 BDO Biotech Briefing, a report from BDO USA LLP analyzing the 10-K SEC filings from companies in the Nasdaq Biotechnology Index (NBI) with revenue of less than $300 million. Read More
When thinking about the annual rankings of the leading U.S. life science clusters, it comes as no great surprise that the Greater Boston and the San Francisco Bay areas head the top 10 list. According to JLL's just-released U.S. Life Sciences Outlook report, those regions consistently attain their rankings because each has the key characteristics that comprise an ideal cluster – notably world-class academic institutions, leading research facilities, a vibrant venture capital community, a closely connected medical community and supportive local and state governments willing to invest heavily in facilities and infrastructure to nurture a thriving life sciences hub. Read More
